Drug profile · INN
cysteamine bitartrate
CYSTAGON
cysteamine bitartrate (CYSTAGON) is a cystine reducing agent. Route of administration: oral. Current US regulatory status: approved.
Drug details — cysteamine bitartrate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 6
- Programs
- 0
- Data quality
- 0.84
Quick answer
cysteamine bitartrate (CYSTAGON) is a cystine reducing agent. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cystine reducing agent
Primary target: Cystine
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Related patents
-
US 9925156
Enterically coated cysteamine, cystamine and derivatives thereof
granted -
US 9925158
Enterically coated cysteamine, cystamine and derivatives thereof
granted -
US 9925157
Enterically coated cysteamine, cystamine and derivatives thereof
granted -
US 9198882
Enterically coated cysteamine, cystamine and derivatives thereof
granted -
US 9192590
Enterically coated cysteamine, cystamine and derivatives thereof
granted -
US 8026284
Enterically coated cystamine, cysteamine and derivatives thereof
granted
Frequently asked questions
What is cysteamine bitartrate?
cysteamine bitartrate (CYSTAGON) is a cystine reducing agent. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for cysteamine bitartrate?
CYSTAGON is a marketed brand name for cysteamine bitartrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cysteamine bitartrate?
cysteamine bitartrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.